Codeveloping Targeted Therapies and Diagnostics: What's in It for Me? : Market Research Report

Codeveloping Targeted Therapies and Diagnostics: What's in It for Me?

Published: Nov. 15, 2006 - 26 Pages

Price reduced due to age.

Executive Summary: Strategic Considerations; Stakeholder Implications; RxDx Products: Balancing Public Benefit and Company Profit; Key Codevelopment Concepts; The FDA Concept Paper; Draft Paper Addresses RxDx Codevelopment Timelines/Steps; Clarifications Requested by Industry; It's All About the Biomarker; Who Has the Biomarkers?; When Is RxDx Development Necessary and When Is It Not?; What's in It for Me?; Incentives to Codevelop an RxDx; Decreasing Costs of RxDx Codevelopment; Increasing Pricing/Reimbursement for RxDx Products; Robbing Rx to Pay Dx; Increasing Market and Patent Exclusivities; Case Study: Herceptin, HER-2 Tests, and the Value of RxDx; Cost-Effectiveness of Herceptin; Cost-Effectiveness of HER-2 Tests; Executive Perspective: Value of RxDx; Detailed Analysis: Cost-Effectiveness of Herceptin; Outlook; RxDx Partnering Challenges; Parallel and Nonparallel RxDx Partnerships; "We Choose to Go to the Moon"; Companies to Watch; It Will Be Done in This Decade
Tables: 1. Ranking of Monoclonal Antibodies by Indication and Worldwide Sales; 2. Select Companion Diagnostic Tests
Figures: 1. Biomarkers and Drug Development; 2. RxDx Codevelopment Process; 3. Chromosome 5: Distribution of Single Nucleotide Polymorphisms; 4. Average Response Rates to "One-Size-Fits-All" Drugs; 5. When to Develop Companion RxDx Products; 6. Perception of Benefit by Different Stakeholders

Abstract

Drug-test (RxDx) companion products pair a drug and a diagnostic test that can tell physicians which patients will benefit most from treatment with the drug. This report examines whether it is appropriate to ask pharmaceutical/biotech and diagnostics companies to develop these products when they may question what benefi t they will receive from such development; after all, these companies are already developing good drugs and good tests to treat many people. We examine the FDA's efforts to encourage development of RxDx products, possible incentives to both drug and diagnostics companies, the companies that we believe are currently suited to fi nd success, and what factors will likely play into this success.

Get the Answers You Need to Shape Your Strategy
The benefits of RxDx companion products could be very high for individual patients and society. However, decisions in the drug and diagnostics industries are based on economics.What will development of such tests cost? How will companies know when it makes financial sense to develop them?

Technology now exists to exploit the information in human genes to make better medicines that treat not just large patient populations but also individual patients through personalized medicine. How can drug and diagnostics companies best benefit from this new knowledge? How can they strike a balance between public benefi t and company profit?

Try as the FDA might to encourage the codevelopment of RxDx products, a lack of obvious economic benefit to the pharmaceutical and diagnostics industries has caused these industries to drag their feet in the development of personalized medicine and RxDx products specifically. What incentives are being considering to encourage development of these products? Can the cost of development be decreased? Should pricing/reimbursement for RxDx products be increased? What other incentives are reasonable?

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Codeveloping Targeted Therapies and Diagnostics: What's in It for Me?

Table of Contents

Abstract